Treatment of CLL has been shifting from chemoimmunotherapy (CIT) only to the use of small molecule inhibitors, such as Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors [4]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.